Some of the main goals of treatments for essential thrombocythemia include reducing disease progression and blood clots while improving symptom burden, but more treatments may be on the horizon ...
Risk stratification replaces “Stage 4” terminology, prioritizing prevention of arterial/venous thrombosis and bleeding events over tumor burden concepts. Diagnostic confirmation typically integrates ...
Preliminary findings from 51 evaluable ET patients showed treatment with INCA033989 monotherapy demonstrated rapid and durable normalization of platelet counts. The Food and Drug Administration (FDA) ...
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Hosted on MSN
Understanding high platelet counts and your health
What it means: Thrombocytosis is a high platelet count, which can make blood too sticky and raise the risk of clot-related complications like stroke or heart attack. Two main types: Reactive ...
DEAR DR. ROACH: Recently, I was diagnosed with essential thrombocythemia. The recommended treatment is the drug hydroxyurea because I turned 60 this past year and have a mutation in the JAK 2 gene. If ...
Please provide your email address to receive an email when new articles are posted on . Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed the study, that ...
Results from a new clinical trial led by Wake Forest University School of Medicine and Atrium Health Levine Cancer shows a new therapy could provide significantly better outcomes for patients with ...
Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...
Hemorrhagic events post-diagnosis in patients with ET significantly increase mortality risk, more than thrombosis or disease progression. Intracranial hemorrhage is the most lethal bleeding ...
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) “The standard of care in essential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results